glp 1 death GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes GLP-1RAs reduce cardiovascular deaths in

Doctor-led weight care across India.

Our blog series on GLP-1 agonists for weight loss is aimed at unpacking the science behind this new frontier in weight management, presenting a detailed overview of how they work, their efficacy, and their role in a holistic approach to health and wellness.

And here we see in IQVIAs two charts the declining share of traditional diabetes therapies with growing new prescriptions for GLP-1 agonists a 5% share in 2019 and a 16% share in 2023

The Bottom Line GLP1 therapies are changing the game for T2D, and their influence is continuing to spread across the broader chronic disease landscape